In:
International Journal of Cancer, Wiley, Vol. 147, No. 1 ( 2020-07), p. 21-32
Abstract:
What's new? Long‐term survival to 15 years among germ cell testicular cancer survivors treated in the cisplatin era, marked by the introduction of cisplatin in the late 1970s, generally has been excellent. Beyond 20 years, however, survival rates decline. In this analysis of data on Norwegian men diagnosed with testicular cancer between 1980 and 2009, an increased overall risk for nongerm cell second cancer was detected among survivors, despite treatment. Risk was elevated in particular beyond 10 years of follow‐up after cisplatin‐based chemotherapy or radiotherapy. Despite reduced treatment intensity, two or more cycles of cisplatin‐based chemotherapy was associated with continuing increased second cancer risk.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8